Talis Biomedical Appoints Former Roche Molecular CEO Heiner Dreismann to Board of Directors, Announces Former Genomic Health CEO Kim Popovits as Lead Independent Director
May 23 2023 - 8:00AM
Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company
dedicated to advancing health equity and outcomes through the
delivery of accurate infectious disease testing in the moment of
need, at the point of care, today announced Heiner Dreismann has
joined its board of directors, effective immediately. Talis Bio
also recently appointed Kim Popovits, who has served as a member of
the board since March 2020, as its lead independent director.
“Heiner’s entrepreneurial vision and track record leading
multiple corporate functions over the course of his 20-year tenure
at Roche Diagnostics are ideal for the opportunities Talis Bio is
pursuing,” said Rob Kelley, chief executive officer at Talis Bio.
“We look forward to benefiting from Heiner’s seasoned perspective
and Kim’s continued support as we execute our plan to deliver
multiple women’s and sexual health tests at the point of care.”
Dr. Dreismann has more than 35 years of experience in the
diagnostic industry and is regarded as a pioneer in the early
adoption of polymerase chain reaction (PCR) technique. From 1985 to
2006, he held multiple executive positions at Roche Diagnostics,
including president and chief executive officer of Roche Molecular
Systems, head of global business development of Roche Diagnostics
and member of Roche’s Global Diagnostic Executive Committee. Dr.
Dreismann currently serves on the boards of several public and
private healthcare companies. He earned a Master of Science degree
in Biology and his Ph.D. in Microbiology/Molecular Biology (summa
cum laude) from the University of Munster in Germany.
“I believe there is a significant opportunity to decentralize
molecular testing, beginning with some of the most pressing needs
in women’s and sexual health that Talis Bio plans to address. I am
impressed by the differentiated design of the Talis One® system and
the manufacturing capabilities the company has established to
support its commercial plan,” said Dr. Dreismann. “I look forward
to collaborating with this impressive team to advance Talis Bio’s
regulatory strategy and product roadmap.”
Ms. Popovits has been a member of the Talis Bio board of
directors since March 2020 and has been elevated to be its lead
independent director. She is the former chairman of the board,
president and chief executive officer of Genomic Health. Under her
leadership, Genomic Health became the world’s leading provider of
genomic-based diagnostic tests that optimized the treatment of
cancer, resulting in an acquisition by Exact Sciences for $3
billion in 2019. Prior to joining Genomic Health in 2002, Ms.
Popovits held multiple senior management roles of increasing
responsibility at Genentech. In addition to Talis Bio, she
currently serves on the boards of several public and private
healthcare companies.
“Talis Bio has made important progress and is now well
positioned to execute on its plans for future growth and value
creation. I welcome Heiner to Talis Bio and look forward to working
with the board and the executive leadership team to deliver on our
mission to address a critical need in serving patients at the point
of care,” said Ms. Popovits.
About Talis BiomedicalTalis Biomedical is
dedicated to advancing health equity and outcomes through the
delivery of accurate infectious disease testing in the moment of
need, at the point of care. The Company plans to develop and
commercialize innovative products on its sample-to-answer Talis
One® system to enable accurate, low cost, and rapid molecular
testing. For more information, visit talisbio.com.
Forward-Looking Statements This press release
may contain forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. Words such as
“may,” “might,” “will,” “would,” “should,” “believe,” “expect,”
“anticipate,” “could,” “estimate,” “continue,” “predict,”
“potential,” “forecast,” “project,” “plan,” “intend” or similar
expressions, or other words that convey uncertainty of future
events or outcomes can be used to identify these forward-looking
statements. Forward-looking statements include statements regarding
our intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things: our plans to advance
our pipeline, including the plans to develop Talis One tests in the
women’s and sexual health markets; the size and potential of our
opportunity in the women’s and sexual health markets; our ability
to capitalize on any competitive advantages; our ability to
position Talis Bio to provide durable value to our shareholders;
the benefits of our regulatory strategy; our future revenue growth
and profit margins; and our ability to lower our cash burn, extend
operations and extend our cash runway. These statements are not
guarantees of future performance and are subject to certain risks,
uncertainties and other factors that could cause actual results and
events to differ materially and adversely from those indicated by
such forward-looking statements including, among others: risks and
uncertainties associated with development and regulatory approval,
the impact to our business from global economic conditions,
including inflationary pressures, the ongoing COVID-19 pandemic and
any related impact on our ability to develop our pipeline products,
our ability to achieve or sustain profitability, our ability to
launch and gain market acceptance for our pipeline products and to
accurately forecast and meet customer demand, our ability to
compete successfully, our ability to enhance our product offerings,
development and manufacturing, capacity constraints or delays in
production of our products, and product defects or failures. These
and other risks and uncertainties are described more fully in the
“Risk Factors” section and elsewhere in our filings with the
Securities and Exchange Commission and available at www.sec.gov,
including in our Annual Report on Form 10-K and Quarterly Reports
on Form 10-Q. These statements are based upon information available
to us as of the date of this press release, and while we believe
such information forms a reasonable basis for such statements, such
information may be limited or incomplete, and our statements should
not be read to indicate that we have conducted an exhaustive
inquiry into, or review of, all potentially available relevant
information. These statements are inherently uncertain and
investors are cautioned not to unduly rely upon these statements.
Any forward-looking statements that we make in this announcement
speak only as of the date of this press release, and Talis Bio
assumes no obligation to update forward-looking statements whether
as a result of new information, future events or otherwise after
the date of this press release, except as required under applicable
law.
Contact Media & InvestorsEmily
Faucetteefaucette@talisbio.com415-595-9407
Talis Biomedical (NASDAQ:TLIS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Talis Biomedical (NASDAQ:TLIS)
Historical Stock Chart
From Oct 2023 to Oct 2024